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Highly active antiretroviral therapy (HAART)
has changed the natural course of HIV dis-
ease. In a majority of patients, complete sup-
pression of viral replication and immunolog-
ical recovery can be accomplished. Despite
these achievements, persons with HIV infec-
tion are at a significant risk for end-stage
organ disease. One third of them are co-
infected with hepatitis C (HCV) and/or hep-
atitis B virus (HBV). Additional causes are 
related to direct or indirect effects of HIV 
itself (eg HIV-associated nephropathy). Solid
organ transplantation (SOT) is often the only
therapeutic option remaining, although HIV
infection was considered a contraindication
before the advent of HAART. However, in 
recent years, a considerable number of HIV-
infected patients has undergone SOT with
encouraging results [1]. In 2001, out of 18,014
US medicare solid organ recipients, 175 were
HIV-positive. With a median follow-up of 
42 months, no significant difference between
HIV-negative and HIV-positive recipients
was found in this retrospective analysis for a
number of variables such as graft survival,
death-censored graft survival, death with
functioning organ or mortality [2]. 
Ragni et al. published the first results of
experience with liver transplantation and
HIV. The results were comparable to the
non-HIV population, with the subgroup of
HCV-positive recipients showing a poorer
outcome [3]. Despite these results, a survey
performed in 2004 among 619 surgeons (all
members of the American Society of Trans-
plant Surgeons) showed that 70% would
accept a HBV or HCV-positive recipient, but
only 36% would accept a HIV-positive pa-
tient, even if his HIV infection was controlled
[4]. This number dropped to 6% when pa-
tients with AIDS were included. Thus, SOT
in HIV-patients is not yet uniformly accepted.
The question of availability of SOT in pa-
tients with a HBV/HCV and HIV coinfection
is all the more important, as disease progres-
sion is accelerated when compared to patients
infected only by HCV or HBV [5].
Interactions between antiretroviral drugs
and immunosuppression have emerged as a
major challenge in HIV-infected patients
after SOT. In addition Stock et al. reported
on a possible increase in the number of rejec-
tion episodes after kidney transplantation in
HIV-infected patients [6].
We assessed the current status of SOT in
HIV-infected patients in Switzerland. With
the use of a structured questionnaire, clinical
course, side effects and drug interactions were
recorded for all HIV-positive solid organ re-
cipients. We included all HIV-positive pa-
tients who had received a solid organ so far in
Switzerland. All patients participated in the
Swiss HIV Cohort Study. The goal of this in-
vestigation was to identify specific problems
associated with SOT and HIV, and to present
our Swiss experience to a broader medical
audience. We wish to contribute to the dis-
cussion about the inclusion of HIV-infected
persons in transplant programs, and to en-
hance awareness of this new therapeutic
modality. The course and outcome of eight
HIV-positive patients transplanted in
Switzerland is described.
Clinical course and cause of end-stage organ
disease (table 1). Five patients received a cadav-
eric liver (two for cirrhosis due to HCV, one
for cirrhosis due to HBV, one for fulminant
hepatitis due to HBV reactivation, and one for
HBV/HCV co-infection with hepatocellular
carcinoma), and three received a cadaveric
kidney/pancreas and kidney (one for end-
stage renal failure due to diabetes, one for ter-
minal kidney disease of unknown aetiology,
one for HIV-associated nephropathy). Me-
dian follow-up was 19 months (range 7–61).
The immunosuppressive regimen is detailed
in table 1. Patient #1 died with liver failure
after HCV recurrence. Patient #4 died with
liver failure due to chronic rejection of the
graft and renal insufficiency after unilateral
nephrectomy for renal carcinoma and im-
munosuppressive drug toxicity. Of the six pa-
tients alive, three liver and two kidney recip-
ient had a good graft function at the time of
analysis. In one patient, the graft failed due to
chronic rejection resulting in dialysis. Four
patients have had rejection episodes. 
Course of HIV-infection. One previously
reported patient was a long-term non pro-
gressor showing stable CD4 cell counts with-
out antiretroviral therapy [7]. One patient had
been diagnosed with a Pneumocystis jiroveci
(carinii) pneumonia earlier. With the excep-
tion of the long-term non progressor all had
experienced nadir CD4 cell counts <200/ml
prior to transplantation. At the time of trans-
plantation, three of these patients had counts
above 200 cells/ml, and four had counts below.
In two of these patients, it is likely that the
concomitant liver cirrhosis prevented a fur-
ther immunological recovery despite full viral
suppression. In the two remaining patients,
transplantation had been performed not
knowing the HIV status in one case, in the
other, only the last value before transplan-
tation was below 200 cells/ml, while all the
earlier CD4 cell counts had been above 
200 cells/ml. Importantly, in all of the 7 HIV-
infected patients under therapy, HIV repli-
cation remained suppressed, and none devel-
oped HIV-related complications. 
Drug interactions and side-effects. In six pa-
tients (#1, 4–8), drug interactions and side ef-
fects necessitated a modification of HAART.
In patient #1, ritonavir-induced inhibition of
CYP3A4 activity led to very high levels of
tacrolimus, and ritonavir was replaced by ri-
tonavir-boosted lopinavir. A combined effect
of mycophenolate mofetil and zidovudine was
responsible for severe anaemia in patient #4.
Mycophenolate mofetil was stopped, and
stavudine given instead of zidovudine. Later,
stavudine was replaced by tenofovir; this
change was made for better control of hepa-
titis B, as tenofovir has excellent activity
against HBV. Patient #5 experienced renal
toxicity probably related to cyclosporine A,
and modification of his tenofovir dose was
necessary. In patient #6, ritonavir-boosted
lopinavir replaced efavirenz at the time of
transplantation, because of concerns of insuf-
ficient viral control by efavirenz. As in patient
#1, this led to very high tacrolimus levels and
a difficult adjustment of therapy. Patient #7
showed low levels of cyclosporine A despite
good adherence. An interaction with ritona-
vir-boosted lopinavir is unlikely because the
low levels persisted after changing to ritona-
vir-boosted atazanavir. This change of ther-
apy was provoked by a massive dyslipidaemia
with cholesterol levels of 20,1 mmol/l, which
was most likely a combined and potentiated
effect of both cyclosporine A and ritonavir-
boosted lopinavir, two drugs known to in-
crease lipid levels. Finally, in patient #8, two
relevant interactions were observed. The
concomitant use of atazanavir and omepra-
zole, a proton pump blocker, led to unde-
tectable blood levels of atazanavir despite reg-
ular intake. Omperazole had been started at
time of transplantation as part “routine” pre-
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vention of gastrointestinal ulceration without
informing the physician in charge of the 
anti-HIV treatment. Despite boosting of
atazanavir with ritonavir and increase of the
dose, reliable levels of atazanavir were only
achieved after discontinuation of omeprazole.
The second observation concerned the inter-
action between ritonavir-boosted atazanavir
with tacrolimus, which necessitated a pro-
gressive lowering of the tacrolimus dose from
an average of 6 mg/day to 0.14 mg/day.
In the Western hemisphere, better con-
trol of HIV infection has led to immunologi-
cal recovery in many patients, and to a greatly
decreased HIV-related mortality and morbid-
ity. Concomitant health-related issues have
emerged as new challenges in this population.
30% of HIV-infected individuals have a 
co-infection with HBV or HCV. The course
of HBV and HCV infection is accelerated in
patients with HIV infection. Additional po-
tential causes of end-stage organ disease are
side effects of drugs, or HIV-related direct or
indirect effects (eg HIV nephropathy). For
these patients, solid organ transplantation is
often the only therapeutic option remaining.
Despite an increasing number of reports
showing a comparable outcome between HIV
and non-HIV-infected solid organ recipients,
this therapeutic modality is still used very 
reluctantly. 
To date, only eight HIV-positive individ-
uals have had a solid organ transplantation in
Switzerland. Since the routine recording of
liver failure-associated deaths in the HIV 
cohort in 1999, a total of 76 patients with
liver-associated death have been reported 
(10 patients/year). (personal communication,
B. Ledergerber). The number of transplanted
patients is therefore small, even if we consider
that a high proportion of the HIV-infected
patients are not easy to manage, and not con-
sidered good candidates for transplantation,
eg due to ongoing injection drug use. On the
other hand, many of these patients have
proved that they are able to adhere to therapy,
as measured by continuous viral suppression,
which is an absolute prerequisite for success
of transplantation. These patients are likely to
succeed after SOT.
Of the eight patients, one died due to
relapse of HCV. Unfortunately, the outcome
after liver transplantation for HCV is not
foreseeable and sometimes disappointing in
both the HIV- and non-HIV-infected recipi-
ents. Relapse of HCV-infection is universal,
and in almost all recipients, treatment for
HCV needs to be restarted. That must be
considered before transplantation, and taken
into account when evaluating a potential
Patient cause of end- type of immuno- rejection graft death opportunistic F/up time comments
# stage disease transplant suppression episodes function infections months
1 HCV cadaveric prednison, no failure death due to none 9 interaction 
liver tacrolimus graft failure: ritonavir
recurrent tacrolimus 
HCV underestimated;
HCV relapse
2 HCV cadaveric cyclosporin A week 1 good alive none 19 HCV relapse
liver after tpl.
3 diabetes cadaveric cyclosporin A, chronic pancreas: ok; alive none 61 long-term non 
mellitus pancreas/ MMF rejection kidney: back progressor
kidney (kidney) on dialysis, (case published in: 
waiting for Am J Transplant 
ReTpl 2003;3:631–3)
4 HBV cadaveric tacrolimus chronic failure death due to CMV infection, 42 no relapse with 
reactivation liver changed to rejection graft and renal genital HSV 2 HBV treatment;
sirolimus failure reactivation renal carcinoma ?
because of nephrectomy ?
chronic dialysis; trans-
rejection; MMF plantation was 
stopped for performed not
anemia knowing HIV
status
5 HBV and cadaveric cyclosporin A none good, alive none 38 haemophilia 
HCV, liver, stopped for treatment cured with the 
cirrhosis and donor renal failure, of HCV transplantation; 
hepatocellular HBSAg + switched to (relapse), HCV relapse
carcinoma sirolimus; MMF and HBV 
stopped when with
ribavirin + 3TC,
Peg. INF tenofovir
were started
6 HBV cirrhosis cadaveric tacrolismus none good, alive none 20 osteoporosis, 
liver (0.5 mg once treatment for tremor, 
a week) HBV with hypertension
tenofovir; 3TC
7 end-stage renal cadaveric cyclosporin A, one good alive none 19 dyslipidaemia  
disease of kidney prednison, probable (max. cholesterol:
unknown MMF 20.1 mmol/l), low 
aetiology cyclosporin levels
8 HIV-associated cadaveric tacrolimus, none good alive none 7 progressive lowering 
nephropathy kidney prednison, of tacrolimus dose
MMF (6 mg/day to
0.14 mg/day), 
eventually, replaced 
by cylosporin A
because of hair loss
HBV: Hepatitis B virus; HCV: Hepatitis C virus; MMF: Mycophenolate mofetil; Peg. INF: Pegylated interferon gamma; Tpl: Transplantation
Table 1
Cause of end-stage organ disease, and transplant-related complications.
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recipient. However, the overall outcome has
been very similar between HIV- and non-
HIV-infected recipients of a kidney or liver. 
A recent retrospective study comparing the
kidney transplantation experience in HIV-
positive patients in the US with 114 deceased
donors and 64 living donors showed a com-
parable graft and patient outcome when com-
pared to the HIV-negative population.
All eight patients were able to success-
fully control their HIV-infection. For many
transplantation teams, an uncontrolled HIV-
infection is considered an exclusion criteria. If
an HIV patient is not able to tolerate an anti-
retroviral therapy due to liver insufficiency, 
or has CD4 counts below 200 cells/ml, trans-
plantation should still be considered if the
HIV-infection is potentially controllable (ie
no multi-resistance of HIV and valid antire-
troviral options) and CD4 cells are above 
100 cells/ml. Detailed inclusion and exclusion
criteria have been published [8].
Complications recorded included rejec-
tion, drug interactions and recurrence of un-
derlying disease. While most of these compli-
cations are well known in HIV-negative solid
organ transplantation, the drug interactions
are challenging and require a close interdisci-
plinary collaboration. Careful monitoring of
these potential problems is crucial to assure a
successful outcome. Availability of drug levels
in a timely manner is mandatory. One impor-
tant point to mention is the potent interaction
between HIV protease inhibitors and im-
munosuppressive agents, in particular the 
calcineurin inhibitors cyclosporine A and
tacrolimus. HIV protease inhibitors are po-
tent inhibitors of the cytochrom P3A4 system
and calcineurin inhibitors are substrates of
this system. Frequent monitoring of blood
levels of these drugs is mandatory, especially
when new drugs are introduced. The use of
the non-nucleoside inhibitor efavirenz, al-
though an inductor of cytochrome P450 3A4,
seems easier to manage together with cal-
cineurin inhibitors as shown in three of our
patients (table 1). Drug interactions should 
be anticipated and changes of HAART made
preferentially before transplantation. Poten-
tially, they could be usefully exploited, even in
HIV-negative patients, to attain more stable
levels of tacrolimus and cyclosporine A, and
to diminish costs.
The relatively high incidence of rejection
in our small series has to be confirmed in
larger studies. However, a higher incidence of
rejection in HIV-positive recipients has re-
cently been reported in the literature [6].
The use of non-ideal organs is a matter
of controversy. One of our patients (#5) re-
ceived a cadaveric liver from a HBs antigen
positive donor, with a good result. HAART,
which includes drugs that are also efficacious
against hepatitis B virus, may have con-
tributed to the good result.
In summary, our favourable experience
and the current data suggests that in selected
patients, SOT is a potential therapeutic op-
tion. Patients with a stable or treatable HIV
infection should no longer be a priori ex-
cluded from solid organ transplantation based
on their HIV status. A close collaboration be-
tween the different teams is mandatory.
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